Author

Kihyun Kim

OpenAlex ID: A5147117014

Patients with relapsed or refractory multiple myeloma who achieved sustained minimal residual disease negativity in the DREAMM-7 trial

2026 · Mar.a-Victoria Mateos, Paweł Robak, et al. · NCODA Oncology and Hematology Meeting Abstracts

Changes in renal function with belantamab mafodotin–containing regimens in patients with relapsed or refractory multiple myeloma and baseline mild or moderate renal impairment: post hoc results from DREAMM-7 and DREAMM-8

2026 · Marcelo Pitombeira de Lacerda, Meletios Dimopoulos, et al. · NCODA Oncology and Hematology Meeting Abstracts

Works count: 2

Citation count:

H-index:

I10-index: